GlassScriptPhysician profile
Justin A Malone
NPI 1689895534
$30,012.07
in general payments reported to CMS, 2019-2025
58 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $1,207 · 2022: $945 · 2023: $327 · 2024: $174 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12,982.83 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $11,812.15 | 2019-2021 | |
| Abbvie INC. | $499.96 | 2019-2025 | |
| Genzyme Corporation | $456.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $378.29 | 2019-2023 | |
| Emd Serono, INC. | $373.97 | 2019-2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $311.01 | 2019-2021 | |
| Boston Scientific Corporation | $269.07 | 2019-2025 | General - Dbs |
| Sk Life Science, INC. | $230.83 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $162.48 | 2021 | |
| Ucb, INC. | $159.44 | 2019-2023 | Nayzilam |
| Jazz Pharmaceuticals INC. | $158.38 | 2019-2025 | |
| Biogen, INC. | $150.00 | 2019 | |
| Amgen INC. | $142.27 | 2019-2022 | |
| Kyowa Kirin, INC. | $138.83 | 2019-2023 | Nourianz |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.